RxDoctor Payments Data
★ My doctorsLook up a doctor →

Mitchell Haut, MD

Hematology & Oncology · Canton, OHNPI 1023015674

Payments from drug & device makers

$312,111in general payments, 2019–2025

Across 363 payments — averaging $859.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$137K
  • Regeneron$41K
  • Sanofi US Services Inc.$30K
  • Bristol Myers Squibb$23K
  • Astrazeneca UK Limited$21K
  • Daiichi Sankyo Inc.$19K
  • plus $41K from 45 others

What the payments were for

  • Food & beverage$3,59995%
  • Education$1815%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Merck11$137,107
Regeneron11$41,001
Sanofi US Services Inc.71$29,690
Bristol Myers Squibb19$23,081
Astrazeneca UK Limited2$21,320
Daiichi Sankyo Inc.23$18,801
Morphosys AG7$11,338
E.r. Squibb & Sons, L.L.C.33$10,115
Incyte Corporation13$9,051
Pfizer6$5,185
Mirati Therapeutics, Inc.2$2,570
Novartis13$211
Genentech USA, Inc.15$201
Eisai Inc.10$194
AstraZeneca11$193
Amgen10$164
Sanofi8$145
Johnson & Johnson(2 entities)8$139
Clovis Oncology, Inc.4$132
GSK5$113
AMAG Pharmaceuticals, Inc.6$110
Lilly USA, LLC7$108
Puma Biotechnology, Inc.8$99
Bayer5$91
Boehringer Ingelheim4$68
Seagen Inc.5$68
Regeneron Healthcare Solutions, Inc.2$65
Beigene USA, Inc.4$62
Partner Therapeutics, Inc.3$59
Astellas Pharma US Inc3$59
Tesaro, Inc.3$48
Lexicon Pharmaceuticals, Inc.2$48
EMD Serono, Inc.3$46
Dendreon Pharmaceuticals LLC2$44
Takeda Pharmaceuticals U.S.A., Inc.3$43
Ipsen Biopharmaceuticals, Inc2$40
Exelixis Inc.2$39
Agios Pharmaceuticals, Inc.2$36
Pharmacyclics LLC, An Abbvie Company2$35
Gilead(2 entities)2$25
Foundation Medicine, Inc.1$22
Secura Bio, Inc.1$21
Helsinn Therapeutics (U.S.), Inc.1$18
Advanced Accelerator Applications1$17
Array Biopharma Inc1$15
Acceleron Pharma, Inc.1$14
AVEO Pharmaceuticals, Inc.1$14
Rigel Pharmaceuticals, Inc.1$12
Shionogi Inc1$12
Jazz Pharmaceuticals Inc.1$12
Heron Therapeutics, Inc.1$10

How this compares

$312,111 in reported general payments places this provider in the 75th percentile of 450 hematology & oncology providers in Ohio.

See all hematology & oncology providers in Ohio →

Medicare billing

Part B allowed, 2024
$57,114
Medicare patients
174
Services billed
590

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Abiraterone Acetate19$7,445
Letrozole74$1,329
Prochlorperazine Maleate41$544
Prednisone21$216
Anastrozole13$197
Acyclovir15$182
Dexamethasone16$181
Triamcinolone Acetonide12$171
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen14$127

Paid to pharmacies, not to this prescriber.

Other hematology & oncology in Canton

See the full list for Ohio →

Where these figures come from

Is this you, or does something look wrong? →